PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24627994-5 2014 To further dissect the mechanisms regulating CD13-dependent trafficking we used the murine model of thioglycollate-induced sterile peritonitis. Thioglycolates 100-114 alanyl (membrane) aminopeptidase Mus musculus 45-49 7512741-8 1994 The ApN catalytic activity and mRNA levels are increased in thioglycollate-elicited as compared to resident peritoneal macrophages. Thioglycolates 60-74 alanyl (membrane) aminopeptidase Mus musculus 4-7 7512741-9 1994 RT-PCR analysis identified a 0.7 kb fragment of the ApN coding sequence which was identical in mouse kidney and thioglycollate-elicited peritoneal macrophages and which has 89% identity with the corresponding rat kidney ApN cDNA sequence. Thioglycolates 112-126 alanyl (membrane) aminopeptidase Mus musculus 52-55 24627994-7 2014 Furthermore, adoptive transfer of wild-type and CD13(KO) primary myeloid cells, or wild-type myeloid cells pre-treated with CD13-blocking antibodies into thioglycollate-challenged wild-type recipients demonstrated fewer CD13(KO) or treated cells in the lavage, suggesting that CD13 expression confers a competitive advantage in trafficking. Thioglycolates 154-168 alanyl (membrane) aminopeptidase Mus musculus 48-52 24627994-7 2014 Furthermore, adoptive transfer of wild-type and CD13(KO) primary myeloid cells, or wild-type myeloid cells pre-treated with CD13-blocking antibodies into thioglycollate-challenged wild-type recipients demonstrated fewer CD13(KO) or treated cells in the lavage, suggesting that CD13 expression confers a competitive advantage in trafficking. Thioglycolates 154-168 alanyl (membrane) aminopeptidase Mus musculus 124-128 24627994-7 2014 Furthermore, adoptive transfer of wild-type and CD13(KO) primary myeloid cells, or wild-type myeloid cells pre-treated with CD13-blocking antibodies into thioglycollate-challenged wild-type recipients demonstrated fewer CD13(KO) or treated cells in the lavage, suggesting that CD13 expression confers a competitive advantage in trafficking. Thioglycolates 154-168 alanyl (membrane) aminopeptidase Mus musculus 124-128 24627994-7 2014 Furthermore, adoptive transfer of wild-type and CD13(KO) primary myeloid cells, or wild-type myeloid cells pre-treated with CD13-blocking antibodies into thioglycollate-challenged wild-type recipients demonstrated fewer CD13(KO) or treated cells in the lavage, suggesting that CD13 expression confers a competitive advantage in trafficking. Thioglycolates 154-168 alanyl (membrane) aminopeptidase Mus musculus 124-128